In a career in journalism, there have been too many occasions when I’ve had to stifle a yawn midway through an interview, desperate for the tech CEO or politician or economic analyst in front of me to say something pithy and interesting.
Excellent response and summary by Keith Valentine - thank you Rory for putting this out there. For dementia, slowing disease progression is considered a success, so if you had a clinical trial of a brand new treatment that halted dementia progression would you stop the clinical trial because it failed to reverse the dementia? I rather think not. "Save sight, change lives" says it all and any disease that irreversibly changes lives is as important as the next. In the new era of "Britain open for Business" and the desire for innovative medical treatments to be brought to the clinic faster, perhaps Wes Streeting needs a briefing paper on this specific example of a treatment that halts the progression of choroideremia, a disease that causes sight loss, for which there are current no treatments and therefore changes lives for good. Thank you again Rory and Keith
Excellent response and summary by Keith Valentine - thank you Rory for putting this out there. For dementia, slowing disease progression is considered a success, so if you had a clinical trial of a brand new treatment that halted dementia progression would you stop the clinical trial because it failed to reverse the dementia? I rather think not. "Save sight, change lives" says it all and any disease that irreversibly changes lives is as important as the next. In the new era of "Britain open for Business" and the desire for innovative medical treatments to be brought to the clinic faster, perhaps Wes Streeting needs a briefing paper on this specific example of a treatment that halts the progression of choroideremia, a disease that causes sight loss, for which there are current no treatments and therefore changes lives for good. Thank you again Rory and Keith
I could feel his frustration in your writing.